Fosun Pharmaceutical Group (02196.HK) disclosed plans for proportional capital reduction across all partners of Suzhou Angel Fund. The company initially participated in establishing this fund in January 2022. Current records show the fund secured commitments totaling RMB176 million (with RMB94.25 million already contributed).

Under the existing structure: - Fosun Pharma (via subsidiary Ningbo Fuying) committed RMB110 million (RMB61.25 million paid) - Xing Sheng Fuying committed RMB3 million (RMB1.5 million paid) - Suzhou Angel Fund of Funds committed RMB63 million (RMB31.5 million paid)

These commitments represent ownership stakes of 62.50%, 1.70%, and 35.80% respectively. With the investment period nearing expiration and considering pre-maturity capital requirements, all partners agreed to implement proportional capital reduction totaling RMB76 million.

Post-reduction adjustments include: - Suzhou Angel Fund's capital commitment will decrease from RMB176 million to RMB100 million - Xing Sheng Fuying's commitment reduces by RMB1.295455 million - Ningbo Fuying's commitment decreases by RMB47.5 million - Suzhou Angel Fund of Funds' commitment lowers by RMB27.204545 million

Notably, ownership percentages remain unchanged before and after this adjustment. Since the reduction involves committed but uncalled capital, no compensation payment will be made to the partners.